FDC Limited, a leading Indian pharmaceutical company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting ANDA approval for its Pilocarpine Hydrochloride Ophthalmic Solution USP in 1%, 2%, and 4% formulations (15 mL). This approval marks a key step for FDC in expanding its presence in the global ophthalmic drug market.
In the exchange filings, FDC Limited shared, “This is to inform you that, the Company has been granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Pilocarpine Hydrochloride Ophthalmic Solution USP, 1%, 2%, and 4% (15 mL).”
Pilocarpine Hydrochloride Ophthalmic Solution is widely used for managing glaucoma and ocular hypertension, providing an effective treatment to reduce intraocular pressure in patients. With the FDA approval, FDC can now market these ophthalmic solutions in the highly regulated U.S. pharmaceutical market, enhancing its portfolio of ophthalmology products.
This approval not only strengthens FDC’s footprint in the U.S. generic drugs sector but also demonstrates the company’s commitment to high-quality, patient-centric medicines.